Unveiling rifampin's impact on OSCC lysate-pulsed DCs: From inflammatory to anti-inflammatory landscape.

Dendritic cells (DCs) play a critical role in immune responses, being essential antigen-presenting cells (APCs) for T cell activation. In the context of cancer immunotherapy, DCs are pivotal for eliciting robust CD4(+) and CD8(+) T cell responses against tumor antigens. However, in oral squamous cell carcinoma (OSCC), DCs encounter challenges due to the immunosuppressive tumor microenvironment (TME). Factors like vascular endothelial growth factor (VEGF) and interleukin (IL)-6 in OSCC hinder DC function and maturation. To address this, current research has focused on enhancing DC immunogenicity to boost anti-tumor immunity. Rifampin, known for its antibacterial properties, presents immunomodulatory effects that could be beneficial in augmenting DC function in cancer therapy. This study investigates the impact of rifampin treatment on OSCC lysate-loaded-DCs. Results show that rifampin enhances the expression of key inflammatory factors while reducing anti-inflammatory mediators in DCs. Moreover, rifampin treatment enhances the immune-stimulatory capabilities of OSCC lysate-loaded-DCs, potentially improving their effectiveness in cancer immunotherapy.